---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-023235"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:31:29.345115+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abeona raises $25M in registered direct offering at $4.03/share to fund EB-101 launch prep

## Summary
- Gross proceeds ~$25M; net ~$22.9M after fees and expenses.
- Issued 3,284,407 shares and pre-funded warrants for 2,919,140 shares at $4.03 per share.
- Proceeds primarily for commercial launch preparation for gene therapy EB-101 (BLA pending).
- Offering led by Nantahala Capital Management; includes Adage Capital Partners and two other institutions.
- Closing expected on or about July 6, 2023, subject to customary conditions.

## SEC filing metadata
- accession: 0001493152-23-023235
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223023235/0001493152-23-023235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223023235/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-023235
- JSON: https://secwatch.observer/filing/0001493152-23-023235.json
- Plain text: https://secwatch.observer/filing/0001493152-23-023235.txt

## Key facts
- Material Agreements
  ABEONA THERAPEUTICS INC. entered into Purchase Agreement with certain existing institutional investors valued at approximately $22.9 million (effective 2023-07-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain existing institutional investors
  - Value: approximately $22.9 million
  - Effective: 2023-07-03
  source text: On July 3, 2023, Abeona Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain existing institutional investors relating to the issuance and sale of an aggregate of (a) 3,284,407 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 2,919,140 shares of the Company’s common stock (the “Pre-Funded Warrants”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315223023235/0001493152-23-023235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.